Finanzen von ABVC Biopharma Inc (ABVC)ABVCABVC Biopharma Inc

Evaluating the bottom line, ABVC Biopharma Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -82.15%, provide a clear picture of how effectively ABVC converts its operational activities into shareholder value.

In the context of the broader market, ABVC competes directly with industry leaders such as ALLR and CANF. With a market capitalization of $22.12M, it holds a leading position in the sector. When comparing efficiency, ABVC's gross margin of N/A stands against ALLR's 100.00% and CANF's 100.00%. Such benchmarking helps identify whether ABVC Biopharma Inc is trading at a premium or discount relative to its financial performance.

The company has reported no revenue for several quarters, with a total revenue of $389,276 in Q3 2024, followed by a drastic drop to $1,966 in Q4 2024 and no revenue thereafter. The gross margin is high at 100% for Q4 2024, but this is not sustainable without revenue generation.